{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T17:06:38Z","timestamp":1789146398996,"version":"build-2803163510"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004735","name":"Hunan Provincial Natural Science Foundation","doi-asserted-by":"publisher","award":["2025JJ60798"],"award-info":[{"award-number":["2025JJ60798"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82202866"],"award-info":[{"award-number":["82202866"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.intimp.2026.117273","type":"journal-article","created":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T21:59:33Z","timestamp":1786485573000},"page":"117273","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Tro-score, a trogocytosis-related transcriptomic signature, identifies CD109 as a therapeutic target for reversing immunosuppression in bladder cancer"],"prefix":"10.1016","volume":"187","author":[{"given":"Jinhui","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minghui","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinbo","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiongbing","family":"Zu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiatong","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianqiao","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenyu","family":"Nie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiyu","family":"Tong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2026.117273_bb0005","article-title":"Developmentally programmed germ cell remodelling by endodermal cell cannibalism","volume":"18","author":"Yusuff","year":"2016","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.intimp.2026.117273_bb0010","article-title":"Cutting edge: CTLs rapidly capture membrane fragments from target cells in a TCR signaling-dependent manner","volume":"166","author":"D","year":"2001","journal-title":"J. Immunol."},{"key":"10.1016\/j.intimp.2026.117273_bb0015","article-title":"Colon cancer cells acquire immune regulatory molecules from tumor-infiltrating lymphocytes by trogocytosis","volume":"118","author":"Jae Hun","year":"2021","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.intimp.2026.117273_bb0020","article-title":"Neutrophils kill antibody-opsonized cancer cells by trogoptosis","volume":"23","author":"Hanke","year":"2018","journal-title":"Cell Rep."},{"key":"10.1016\/j.intimp.2026.117273_bb0025","article-title":"Acquired resistance for immune checkpoint inhibitors in cancer immunotherapy: challenges and prospects","volume":"14","author":"Xunrui","year":"2022","journal-title":"Aging (Albany NY)"},{"issue":"3","key":"10.1016\/j.intimp.2026.117273_bb0030","doi-asserted-by":"crossref","DOI":"10.1002\/imt2.70033","article-title":"Efficacy and biomarker analysis of neoadjuvant disitamab vedotin (RC48-ADC) combined immunotherapy in patients with muscle-invasive bladder cancer: a multi-center real-world study","volume":"4","author":"Hu","year":"2025","journal-title":"iMeta"},{"key":"10.1016\/j.intimp.2026.117273_bb0035","article-title":"Acquired resistance to immune checkpoint inhibitors","volume":"37","author":"Adam","year":"2020","journal-title":"Cancer Cell"},{"key":"10.1016\/j.intimp.2026.117273_bb0040","article-title":"Trogocytosis in CAR immune cell therapy: a key mechanism of tumor immune escape","volume":"22","author":"Yizhao","year":"2024","journal-title":"Cell Commun. Signal."},{"key":"10.1016\/j.intimp.2026.117273_bb0045","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"B","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.intimp.2026.117273_bb0050","article-title":"Pembrolizumab as neoadjuvant therapy before radical cystectomy in patients with muscle-invasive urothelial bladder carcinoma (PURE-01): an open-label, single-arm, phase II study","volume":"36","author":"Andrea","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.intimp.2026.117273_bb0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2024.107230","article-title":"Effect of FGFR alteration on prognosis in 1963 urothelial carcinoma patients with immune checkpoint inhibitors: implying combination of FGFR inhibitor and immunotherapy for FGFR-altered urothelial carcinoma","volume":"205","author":"Song","year":"2024","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.intimp.2026.117273_bb0060","article-title":"A systematic review and network meta analysis of first-line immunotherapy for advanced urothelial carcinoma","volume":"9","author":"Liu","year":"2026","journal-title":"Cancer Drug Resist."},{"key":"10.1016\/j.intimp.2026.117273_bb0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2024.107543","article-title":"Efficacy and safety of selective pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitors in FGFR-altered urothelial carcinoma","volume":"211","author":"Song","year":"2025","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.intimp.2026.117273_bb0070","article-title":"Siglec15 shapes a non-inflamed tumor microenvironment and predicts the molecular subtype in bladder cancer","volume":"11","author":"Jiao","year":"2021","journal-title":"Theranostics"},{"key":"10.1016\/j.intimp.2026.117273_bb0075","article-title":"TGF\u03b2 attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells","volume":"554","author":"Sanjeev","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.intimp.2026.117273_bb0080","article-title":"A consensus molecular classification of muscle-invasive bladder cancer","volume":"77","author":"Aur\u00e9lie","year":"2019","journal-title":"Eur. Urol."},{"key":"10.1016\/j.intimp.2026.117273_bb0085","article-title":"Neoadjuvant immunotherapy, chemotherapy, and combination therapy in muscle-invasive bladder cancer: a multi-center real-world retrospective study","volume":"3","author":"Jiao","year":"2022","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.intimp.2026.117273_bb0090","article-title":"Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response","volume":"24","author":"Peng","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.intimp.2026.117273_bb0095","article-title":"Cold and hot tumors: from molecular mechanisms to targeted therapy","volume":"9","author":"Bo","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.intimp.2026.117273_bb0100","article-title":"Immunologic tumor microenvironment modulators for turning cold tumors hot","volume":"44","author":"Gholam-Reza","year":"2024","journal-title":"Cancer Commun (Lond)"},{"key":"10.1016\/j.intimp.2026.117273_bb0105","article-title":"Gemcitabine-resistant biomarkers in bladder cancer are associated with tumor-immune microenvironment","volume":"9","author":"Song","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.intimp.2026.117273_bb0110","article-title":"Tumor-intrinsic oncogene pathways mediating immune avoidance","volume":"5","author":"Stefani","year":"2016","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.intimp.2026.117273_bb0115","article-title":"In vivo CRISPR screens identify a dual function of MEN1 in regulating tumor-microenvironment interactions","volume":"56","author":"Peiran","year":"2024","journal-title":"Nat. Genet."},{"key":"10.1016\/j.intimp.2026.117273_bb0120","article-title":"T cell exclusion, immune privilege, and the tumor microenvironment","volume":"348","author":"Johanna","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.intimp.2026.117273_bb0125","article-title":"Clinical and molecular features of acquired resistance to immunotherapy in non-small cell lung cancer","volume":"42","author":"Danish","year":"2024","journal-title":"Cancer Cell"},{"key":"10.1016\/j.intimp.2026.117273_bb0130","article-title":"ATF3 and CH25H regulate effector trogocytosis and anti-tumor activities of endogenous and immunotherapeutic cytotoxic T lymphocytes","volume":"34","author":"Zhen","year":"2022","journal-title":"Cell Metab."},{"key":"10.1016\/j.intimp.2026.117273_bb0135","article-title":"Outsmarting trogocytosis to boost CAR NK\/T cell therapy","volume":"22","author":"Faezeh","year":"2023","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.intimp.2026.117273_bb0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2025.156375","article-title":"Modulating metabolism to improve the therapeutic outcomes of CAR cell therapies: from bench to bedside","volume":"173","author":"Li","year":"2025","journal-title":"Metabolism"},{"key":"10.1016\/j.intimp.2026.117273_bb0145","doi-asserted-by":"crossref","first-page":"432","DOI":"10.21147\/j.issn.1000-9604.2025.03.11","article-title":"Immune cell metabolism in cancer drug resistance: advances in target discovery and clinical translation","volume":"37","author":"Sun","year":"2025","journal-title":"Chin. J. Cancer Res."},{"key":"10.1016\/j.intimp.2026.117273_bb0150","article-title":"Tracing the evolution of sex hormones and receptor-mediated immune microenvironmental differences in prostate and bladder cancers: from embryonic development to disease","volume":"12","author":"Li","year":"2025","journal-title":"Adv Sci (Weinh)"},{"key":"10.1016\/j.intimp.2026.117273_bb0155","article-title":"Trogocytosis-mediated intracellular signaling in CD4(+) T cells drives T(H)2-associated effector cytokine production and differentiation","volume":"202","author":"Jim","year":"2019","journal-title":"J. Immunol."},{"key":"10.1016\/j.intimp.2026.117273_bb0160","article-title":"Trogocytosis of CAR molecule regulates CAR-T cell dysfunction and tumor antigen escape","volume":"8","author":"You","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.intimp.2026.117273_bb0165","article-title":"Lymphocytes and trogocytosis-mediated signaling","volume":"10","author":"Jim","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.intimp.2026.117273_bb0170","article-title":"Immune microenvironment profiles of tumor immune equilibrium and immune escape states of mouse sarcoma","volume":"340","author":"Xi","year":"2013","journal-title":"Cancer Lett."},{"key":"10.1016\/j.intimp.2026.117273_bb0175","article-title":"IFN\u03b3 is a central node of cancer immune equilibrium","volume":"42","author":"Michael","year":"2023","journal-title":"Cell Rep."},{"key":"10.1016\/j.intimp.2026.117273_bb0180","article-title":"Primary, adaptive, and acquired resistance to cancer immunotherapy","volume":"168","author":"Padmanee","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.intimp.2026.117273_bb0185","article-title":"PARPi triggers the STING-dependent immune response and enhances the therapeutic efficacy of immune checkpoint blockade independent of BRCAness","volume":"79","author":"Jianfeng","year":"2018","journal-title":"Cancer Res."},{"key":"10.1016\/j.intimp.2026.117273_bb0190","article-title":"Tumor mutational burden and immune infiltration as independent predictors of response to neoadjuvant immune checkpoint inhibition in early TNBC in GeparNuevo","volume":"31","author":"T","year":"2020","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.intimp.2026.117273_bb0195","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpha.2025.101253","article-title":"Integrating explainable deep learning with multi-omics for screening progressive diagnostic biomarkers of hepatocellular carcinoma covering the \u201cinflammation-cancer\u201d transformation","volume":"15","author":"Li","year":"2025","journal-title":"J Pharm Anal"},{"key":"10.1016\/j.intimp.2026.117273_bb0200","doi-asserted-by":"crossref","first-page":"1612229","DOI":"10.3389\/pore.2025.1612229","article-title":"Synergistic changes in bystander CD8 and conventional CD4 T cells during neoadjuvant chemoimmunotherapy for non-small cell lung cancer reveal treatment response","volume":"31","author":"Wu","year":"2025","journal-title":"Pathol. Oncol. Res."},{"key":"10.1016\/j.intimp.2026.117273_bb0205","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1002\/pca.3523","article-title":"A comprehensive analysis of volatile and nonvolatile components in Berberis fortunei and its inhibition against HT29 colorectal Cancer cells through GC-IMS, LC-QTOF-MS, and docking-based network analysis","volume":"36","author":"Liu","year":"2025","journal-title":"Phytochem. Anal."},{"key":"10.1016\/j.intimp.2026.117273_bb0210","doi-asserted-by":"crossref","DOI":"10.1002\/imt2.70130","article-title":"Patient-derived organoid-immune co-cultures integrated with multi-omics reveal immunotherapy resistance mechanisms in urothelial carcinoma","volume":"5","author":"Jiang","year":"2026","journal-title":"Imeta"}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576926011197?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576926011197?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T16:12:00Z","timestamp":1789143120000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576926011197"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":42,"alternative-id":["S1567576926011197"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2026.117273","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tro-score, a trogocytosis-related transcriptomic signature, identifies CD109 as a therapeutic target for reversing immunosuppression in bladder cancer","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2026.117273","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"117273"}}